title: Diagnostic performance of whole body dual modality 18F-FDG PET/CT imaging for N- and M-staging of malignant melanoma: experience with 250 consecutive patients.
abstract: OBJECTIVE
  To assess the diagnostic performance of positron emission tomography/computed tomography (PET/CT) using (18)F-fluorodeoxyglucose (FDG) for N- and M-staging of cutaneous melanoma.
  
  
  METHODS
  This is a retrospective and blinded study of 250 consecutive patients (105 women, 145 men; age 58 +/- 16 years) who underwent FDG-PET/CT for staging of cutaneous melanoma at different time points in the course of disease. Whole-body FDG-PET/CT was performed 101 +/- 21 minutes postinjection of 371 +/- 41 MBq FDG. Diagnostic accuracy for N- and M-staging was determined for CT alone, PET alone, and PET/CT.
  
  
  RESULTS
  PET/CT detected significantly more visceral and nonvisceral metastases than PET alone and CT alone (98.7%, 88.8%, and 69.7%, respectively). PET/CT imaging thus provided significantly more accurate interpretations regarding overall N- and M-staging than PET alone and CT alone. Overall N- and M-stage was correctly determined by PET/CT in 243 of 250 patients (97.2%; 95% CI, 95.2% to 99.4%) compared with 232 patients (92.8%; 95% CI, 89.6% to 96.0%) by PET, and 197 patients (78.8%; 95% CI, 73.7% to 83.9%) by CT. All differences were significant. Accuracy of PET/CT was significantly higher than that of PET and CT for M-staging (0.98 v 0.93 and 0.84) and significantly higher than that of CT for N-Staging (0.98 v 0.86). Change of treatment according to PET/CT findings occurred in 121 patients (48.4%).
  
  
  CONCLUSIONS
  The diagnostic performance of FDG-PET/CT for N- and M-staging of melanoma patients suggests its use for whole-body tumor staging, especially for detection or exclusion of distant metastases.
authors.affiliation: Department of Nuclear Medicine, University Hospital Bonn, Bonn, Germany. michael.reinhardt@ukb.uni-bonn.de
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Reinhardt
authors.forename: Alexius Y
authors.initials: AY
authors.lastname: Joe
authors.forename: Ursula
authors.initials: U
authors.lastname: Jaeger
authors.forename: Andrea
authors.initials: A
authors.lastname: Huber
authors.forename: Alexander
authors.initials: A
authors.lastname: Matthies
authors.forename: Jan
authors.initials: J
authors.lastname: Bucerius
authors.forename: Roland
authors.initials: R
authors.lastname: Roedel
authors.forename: Holger
authors.initials: H
authors.lastname: Strunk
authors.forename: Thomas
authors.initials: T
authors.lastname: Bieber
authors.forename: Hans-Juergen
authors.initials: HJ
authors.lastname: Biersack
authors.forename: Thomas
authors.initials: T
authors.lastname: Tüting
mesh_terms: D000328:Adult; D000368:Aged; D005260:Female; D019788:Fluorodeoxyglucose F18; D006801:Humans; D008297:Male; D008545:Melanoma / Q000175:diagnosis* / Q000000981:diagnostic imaging / Q000473:pathology; D008875:Middle Aged; D009367:Neoplasm Staging; D049268:Positron-Emission Tomography; D019275:Radiopharmaceuticals; D012680:Sensitivity and Specificity; D012878:Skin Neoplasms / Q000175:diagnosis* / Q000000981:diagnostic imaging / Q000473:pathology; D014057:Tomography, X-Ray Computed
chemical_list: D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18